M. Nicolson

24.8k total citations · 2 hit papers
112 papers, 10.8k citations indexed

About

M. Nicolson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. Nicolson has authored 112 papers receiving a total of 10.8k indexed citations (citations by other indexed papers that have themselves been cited), including 73 papers in Pulmonary and Respiratory Medicine, 70 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in M. Nicolson's work include Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Diagnosis and Treatment (25 papers) and Lung Cancer Research Studies (17 papers). M. Nicolson is often cited by papers focused on Lung Cancer Treatments and Mutations (51 papers), Lung Cancer Diagnosis and Treatment (25 papers) and Lung Cancer Research Studies (17 papers). M. Nicolson collaborates with scholars based in United Kingdom, United States and Ireland. M. Nicolson's co-authors include David Cunningham, Timothy Iveson, F. Lofts, J.H. Scarffe, Stephen Falk, Sally Stenning, Ruth E. Langley, Monica Verma, J N Thompson and William Allum and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

M. Nicolson

109 papers receiving 10.6k citations

Hit Papers

Perioperative Chemotherap... 2006 2026 2012 2019 2006 2008 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
    2006 4.5k citations David Cunningham, M. Nicolson et al. profile →
  2. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
    2008 1.7k citations David Cunningham, Timothy Iveson et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
M. Nicolson 7.9k 4.5k 4.2k 2.3k 1.3k 112 10.8k
H. Wilke 5.9k 0.7× 3.7k 0.8× 3.7k 0.9× 1.3k 0.5× 942 0.7× 142 8.3k
David B. Smith 4.7k 0.6× 3.0k 0.7× 3.1k 0.7× 1.6k 0.7× 642 0.5× 58 7.4k
Timothy Iveson 10.3k 1.3× 9.2k 2.0× 8.4k 2.0× 2.7k 1.2× 2.0k 1.5× 117 17.1k
Isabelle Ray‐Coquard 5.5k 0.7× 7.0k 1.6× 3.6k 0.9× 2.3k 1.0× 2.8k 2.2× 418 16.7k
Narikazu Boku 10.0k 1.3× 8.1k 1.8× 6.3k 1.5× 3.1k 1.3× 1.8k 1.4× 541 15.3k
Ruth E. Langley 6.5k 0.8× 2.8k 0.6× 4.2k 1.0× 1.9k 0.8× 910 0.7× 104 9.0k
Stephen Falk 7.7k 1.0× 4.9k 1.1× 5.6k 1.3× 2.1k 0.9× 840 0.7× 123 11.4k
Kei Muro 8.6k 1.1× 9.7k 2.1× 5.6k 1.3× 2.1k 0.9× 3.0k 2.3× 598 16.8k
Giuseppe Aprile 5.0k 0.6× 5.6k 1.2× 2.5k 0.6× 1.3k 0.6× 2.0k 1.6× 232 9.8k
C. Boni 5.5k 0.7× 11.0k 2.4× 3.3k 0.8× 729 0.3× 1.7k 1.3× 122 13.9k

Countries citing papers authored by M. Nicolson

Since Specialization
Citations

This map shows the geographic impact of M. Nicolson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Nicolson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Nicolson more than expected).

Fields of papers citing papers by M. Nicolson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Nicolson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Nicolson. The network helps show where M. Nicolson may publish in the future.

Co-authorship network of co-authors of M. Nicolson

This figure shows the co-authorship network connecting the top 25 collaborators of M. Nicolson. A scholar is included among the top collaborators of M. Nicolson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Nicolson. M. Nicolson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicolson, M., et al.. (2024). An unusually dense bloom of the cyanobacterium Gloeotrichia echinulata in Loch Watten, a Scottish highland loch, during July 2023. Biodiversity Heritage Library (Smithsonian Institution). 28(2).
2.
Wasan, Harpreet, Jiazhao Wang, Elaine McCartney, et al.. (2023). LBA100 CUP-ONE trial: A prospective double-blind validation of molecular classifiers in the diagnosis of cancer of unknown primary and clinical outcomes. Annals of Oncology. 34. S1339–S1339. 2 indexed citations
3.
Zhang, Chu, Linda Lawson, Ivan Depasquale, et al.. (2022). TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. Frontiers in Immunology. 12. 763877–763877. 12 indexed citations
4.
Nicolson, M.. (2019). ES05.01 Lung Cancer Survival: Progress and Challenges. Journal of Thoracic Oncology. 14(10). S24–S24. 2 indexed citations
5.
Fennell, Dean A., Sarah Danson, Martin Förster, et al.. (2018). MA12.05 Phase 1 Study of HSP90 Inhibitor Ganetespib with Pemetrexed and Cisplatin/Carboplatin Chemotherapy for Pleural Mesothelioma. Journal of Thoracic Oncology. 13(10). S397–S397. 2 indexed citations
6.
7.
Cree, Ian A., Richard Booton, Paul Cane, et al.. (2016). PD‐L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology. 69(2). 177–186. 65 indexed citations
8.
Rosell, Rafael, Elia Neninger, M. Nicolson, et al.. (2016). Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC. Journal of Thoracic Oncology. 11(11). 1954–1961. 11 indexed citations
9.
Grose, Derek, Graham Devereux, Louise Brown, et al.. (2014). Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response. PubMed. 2014. 1–10. 6 indexed citations
10.
Smith, Sally A., Shona Fielding, Peter Murchie, et al.. (2013). Reducing time before consulting with symptoms of lung cancer: randomised controlled trial. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam). 1 indexed citations
11.
Kerr, Keith M., et al.. (2013). Serpin B3 Is Associated with Poor Survival after Chemotherapy and Is a Potential Novel Predictive Biomarker in Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(12). 1502–1509. 8 indexed citations
12.
Nicolson, M., Dean A. Fennell, David Ferry, et al.. (2013). Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial. Journal of Thoracic Oncology. 8(7). 930–939. 49 indexed citations
13.
Smith, Sarah, Peter Murchie, Graham Devereux, et al.. (2012). Developing a complex intervention to reduce time to presentation with symptoms of lung cancer. British Journal of General Practice. 62(602). e605–e615. 23 indexed citations
14.
Grose, Derek, Graham Devereux, Louise Brown, et al.. (2011). Variation in Comorbidity and Clinical Management in Patients Newly Diagnosed with Lung Cancer in Four Scottish Centers. Journal of Thoracic Oncology. 6(3). 500–509. 15 indexed citations
15.
Coghlin, Caroline, et al.. (2010). Quantitative Analysis of Tumor in Bronchial Biopsy Specimens. Journal of Thoracic Oncology. 5(4). 448–452. 70 indexed citations
16.
Blackhall, Fiona, Mary O’Brien, Peter Schmid, et al.. (2010). A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(8). 1285–1288. 34 indexed citations
17.
18.
Kerr, Keith M., et al.. (2007). P1-166: Influence of tumour patterns in mixed-type adenocarcinoma on post-operative survival. Journal of Thoracic Oncology. 2(8). S801–S802. 6 indexed citations
19.
20.
Groen, Harry J.M., Jan P. van Meerbeeck, David Gilligan, et al.. (2005). The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer (NSCLC) : data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial. European Journal of Cancer Supplements. 3(2). 323–324. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Wilke Breakdown of academic impact, for papers by David B. Smith Breakdown of academic impact, for papers by Timothy Iveson Breakdown of academic impact, for papers by Isabelle Ray‐Coquard Breakdown of academic impact, for papers by Narikazu Boku Breakdown of academic impact, for papers by Ruth E. Langley Breakdown of academic impact, for papers by Stephen Falk Breakdown of academic impact, for papers by Kei Muro Breakdown of academic impact, for papers by Giuseppe Aprile Breakdown of academic impact, for papers by C. Boni
Rankless by CCL
2026